PI3K/AKT/mTOR inhibitors have significant antitumor activity in ovarian cancer cells with high AKT/mTORC1 activity but only a slight effect in ovarian cancer cells with low AKT/mTORC1 activity [30,31]. This evidence concerns the gene PIK3CA and ovarian carcinoma.